FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Medexus Announces Fiscal Q3 2024 Results
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Medexus Fully Repays Convertible Debentures In Cash At Maturity

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.